Polyurethane Meniscal Scaffold for the Treatment of Partial Meniscal Deficiency: 5-Year Follow-up Outcomes: A European Multicentric Study.


Journal

The American journal of sports medicine
ISSN: 1552-3365
Titre abrégé: Am J Sports Med
Pays: United States
ID NLM: 7609541

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 9 4 2020
medline: 19 4 2022
entrez: 9 4 2020
Statut: ppublish

Résumé

A biodegradable polyurethane scaffold was developed to treat patients with the challenging clinical condition of painful partial meniscal defects. The use of an acellular polyurethane scaffold in patients with symptomatic partial meniscal defects would result in both midterm pain relief and improved function. Case series; Level of evidence, 4. A total of 155 patients with symptomatic partial meniscal defects (101 medial and 54 lateral) were implanted with a polyurethane scaffold in a prospective, single-arm, multicentric study with a minimum 5-year follow-up. Clinical outcomes were measured with the visual analog scale for pain, International Knee Documentation Committee subjective knee evaluation form, Lysholm knee scale, and Knee injury and Osteoarthritis Outcome Score at baseline and at 2- and 5-year follow-ups. Magnetic resonance imaging (MRI) was used to evaluate the knee joint, meniscal implant, and meniscal extrusion. Kaplan-Meier survival analysis was also performed. Removal of the scaffold, conversion to a meniscal transplant, and unicompartmental/total knee arthroplasty were used as endpoints. Eighteen patients were lost to follow-up (11.6%). The patients who were included in this study showed significant clinical improvement after surgery as indicated by the different outcome measures ( The polyurethane meniscal implant was able to improve knee joint function and reduce pain in patients with segmental meniscal deficiency over 5 years after implantation. The MRI appearance of this scaffold was different from the original meniscal tissue at the midterm follow-up. The treatment survival rates of 87.9% of the medial scaffolds and 86.9% of the lateral scaffolds in the present study compared favorably with those published concerning meniscal allograft transplantation after total meniscectomy.

Sections du résumé

BACKGROUND
A biodegradable polyurethane scaffold was developed to treat patients with the challenging clinical condition of painful partial meniscal defects.
HYPOTHESIS
The use of an acellular polyurethane scaffold in patients with symptomatic partial meniscal defects would result in both midterm pain relief and improved function.
STUDY DESIGN
Case series; Level of evidence, 4.
METHODS
A total of 155 patients with symptomatic partial meniscal defects (101 medial and 54 lateral) were implanted with a polyurethane scaffold in a prospective, single-arm, multicentric study with a minimum 5-year follow-up. Clinical outcomes were measured with the visual analog scale for pain, International Knee Documentation Committee subjective knee evaluation form, Lysholm knee scale, and Knee injury and Osteoarthritis Outcome Score at baseline and at 2- and 5-year follow-ups. Magnetic resonance imaging (MRI) was used to evaluate the knee joint, meniscal implant, and meniscal extrusion. Kaplan-Meier survival analysis was also performed. Removal of the scaffold, conversion to a meniscal transplant, and unicompartmental/total knee arthroplasty were used as endpoints.
RESULTS
Eighteen patients were lost to follow-up (11.6%). The patients who were included in this study showed significant clinical improvement after surgery as indicated by the different outcome measures (
CONCLUSION
The polyurethane meniscal implant was able to improve knee joint function and reduce pain in patients with segmental meniscal deficiency over 5 years after implantation. The MRI appearance of this scaffold was different from the original meniscal tissue at the midterm follow-up. The treatment survival rates of 87.9% of the medial scaffolds and 86.9% of the lateral scaffolds in the present study compared favorably with those published concerning meniscal allograft transplantation after total meniscectomy.

Identifiants

pubmed: 32267737
doi: 10.1177/0363546520913528
doi:

Substances chimiques

Polyurethanes 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1347-1355

Auteurs

Cecile Toanen (C)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Aad Dhollander (A)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Paolo Bulgheroni (P)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Giuseppe Filardo (G)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Stefano Zaffagnini (S)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Tim Spalding (T)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Joan Carles Monllau (JC)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Pablo Gelber (P)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Rene Verdonk (R)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Philippe Beaufils (P)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Nicolas Pujol (N)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Erica Bulgheroni (E)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Laura Asplin (L)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Peter Verdonk (P)

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH